Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Kintara Therapeutics Inc
KTRACurrent price
0.18 USD
+0.012 USD (+6.88%)
Last closed
0.19 USD
Company
www.kintara.com
ISIN
US49720K1016
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
9 212 969 USD
Yield for 12 month
-95.84 %
1Y
3Y
5Y
10Y
15Y
KTRA
Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a late stage photodynamic therapy for the treatment of cutaneous metastatic breast cancer, basal cell carcinoma nevus syndrome, and access graft failure in hemodialysis patients. Kintara Therapeutics, Inc. has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California. Address: 9920 Pacific Heights Blvd, San Diego, CA, United States, 92121
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
14 USDP/E ratio
–Dividend Yield
–Current Year
–
Last Year
–
Current Quarter
–
Last Quarter
–
Current Year
-60 000 USD
Last Year
-60 000 USD
Current Quarter
-8 000 USD
Last Quarter
-15 000 USD
Key Figures KTRA
1 year
3 years
5 years
10 years
EBITDA
-9 362 000 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-82.96 %
PEG Ratio
–
Return On Equity TTM
-192.23 %
Wall Street Target Price
14 USD
Revenue TTM
–
Book Value
-0.078 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
–
Dividend Yield
–
Gross Profit TTM
–
Earnings per share
-2.32 USD
Diluted Eps TTM
-2.32 USD
Most Recent Quarter
I 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics KTRA
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History KTRA
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
1:50
Payout Ratio
–
Last Split Date
14.11.2022
Dividend Date
08.05.2019
Stock Valuation KTRA
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
–
Price Sales TTM
–
Enterprise Value EBITDA
-1.3694
Price Book MRQ
7.8075
Financials KTRA
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators KTRA
For 52 weeks
0.081 USD
4.59 USD
50 Day MA
0.22 USD
Shares Short Prior Month
1 526 057
200 Day MA
0.18 USD
Short Ratio
0.73
Shares Short
1 190 667
Short Percent
2.15 %
BeatStart